A Cautiously Optimistic Outlook of a Designer Therapy for 1% of Duchenne Muscular Dystrophy Patients

Duan D , Goemans N , Takeda S , et al. Duchenne muscular dystrophy. Nat Rev Dis Primers, 2021; 7:13.

Verhaart IEC , Aartsma-Rus A . Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol, 2019; 15:373–386.

Olson EN . Toward the correction of muscular dystrophy by gene editing. Proc Natl Acad Sci U S A, 2021; 118:e2004840117.

Wasala NB , Hakim CH , Yang NN , et al. Questions answered and unanswered by the first CRISPR editing study in the canine model of Duchenne muscular dystrophy. Hum Gene Ther, 2019; 30:535–543.

Duan D . Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients. Hum Gene Ther, 2018; 29:733–736.

Takeda S , Clemens PR , Hoffman EP . Exon-skipping in Duchenne muscular dystrophy. J Neuromuscul Dis 2021 [Epub ahead of print]; DOI: 10.3233/JND-210682.

Mitelman O , Abdel-Hamid HZ , Byrne BJ , et al. A combined prospective and retrospective comparison of long-term functional outcomes suggests delayed loss of ambulation and pulmonary decline with long-term eteplirsen treatment. J Neuromuscul Dis 2021 [Epub ahead of print]; DOI: 10.3233/JND-210665.

Gushchina LV , Frair EC , Rohan N , et al. Lack of toxicity in nonhuman primates receiving clinically relevant doses of an AAV9.U7snRNA vector designed to induce DMD exon 2 skipping. Hum Gene Ther, 2021; 32:882–894.

Wein N , Dunn DM , Waldrop MA , et al. Absence of significant off-target splicing variation with a U7snRNA vector targeting DMD exon 2 duplications. Hum Gene Ther 2021 [Epub ahead of print]; DOI: 10.1089/hum.2020.315.

Simmons TR , Vetter TA , Huang N , et al. Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping. Mol Ther Methods Clin Dev, 2021; 21:325–340.

Wein N , Vulin A , Falzarano MS , et al. Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nat Med, 2014; 20:992–1000.

Hinderer C , Katz N , Buza EL , et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther, 2018; 29:285–298.

Hordeaux J , Buza EL , Dyer C , et al. Adeno-associated virus-induced dorsal root ganglion pathology. Hum Gene Ther, 2020; 31:808–818.

Hordeaux J , Buza EL , Jeffrey B , et al. MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates. Sci Transl Med, 2020; 12:eaba9188.

Waldrop MA , Lawlor MW , Vetter T , et al. Gene therapy for duchenne muscular dystrophy due to duplications of exon 2 using the scAAV9.U7-ACCA vector: 6–12 months clinical follow up. Mol Ther, 2021; 29:289.

Mendell JR , Al-Zaidy S , Shell R , et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, 2017; 377:1713–1722.